Christian Young
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 10 | 2024 | 625 | 2.020 |
Why?
| Head and Neck Neoplasms | 8 | 2024 | 543 | 1.730 |
Why?
| Phosphatidylinositol 3-Kinases | 9 | 2022 | 360 | 1.200 |
Why?
| Receptor, ErbB-2 | 10 | 2017 | 326 | 1.140 |
Why?
| Receptor, ErbB-3 | 7 | 2017 | 44 | 1.130 |
Why?
| Mouth Neoplasms | 3 | 2023 | 85 | 1.090 |
Why?
| Breast Neoplasms | 12 | 2017 | 2140 | 1.070 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2023 | 64 | 0.800 |
Why?
| Mammary Glands, Animal | 5 | 2015 | 120 | 0.720 |
Why?
| Cell Line, Tumor | 19 | 2024 | 3202 | 0.710 |
Why?
| Mammary Neoplasms, Experimental | 4 | 2014 | 66 | 0.710 |
Why?
| Transforming Growth Factor beta | 6 | 2024 | 455 | 0.700 |
Why?
| Precancerous Conditions | 1 | 2022 | 163 | 0.690 |
Why?
| Proto-Oncogene Proteins c-akt | 9 | 2017 | 431 | 0.650 |
Why?
| Signal Transduction | 16 | 2020 | 4926 | 0.580 |
Why?
| ErbB Receptors | 4 | 2022 | 605 | 0.570 |
Why?
| Mammary Neoplasms, Animal | 3 | 2015 | 30 | 0.560 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 5 | 2020 | 81 | 0.560 |
Why?
| Mice, Nude | 11 | 2020 | 682 | 0.500 |
Why?
| Paracrine Communication | 1 | 2015 | 61 | 0.470 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 169 | 0.450 |
Why?
| Protein Kinase Inhibitors | 3 | 2017 | 890 | 0.430 |
Why?
| Tumor Microenvironment | 6 | 2024 | 631 | 0.420 |
Why?
| Phosphatidylinositol 3-Kinase | 2 | 2023 | 26 | 0.410 |
Why?
| Smad7 Protein | 4 | 2023 | 18 | 0.400 |
Why?
| Mice | 25 | 2024 | 16915 | 0.380 |
Why?
| Glucose Transporter Type 1 | 1 | 2011 | 49 | 0.360 |
Why?
| B7-H1 Antigen | 2 | 2024 | 195 | 0.360 |
Why?
| Animals | 33 | 2024 | 35309 | 0.350 |
Why?
| Stomatitis | 2 | 2021 | 14 | 0.340 |
Why?
| Mucositis | 2 | 2021 | 19 | 0.340 |
Why?
| Cell Proliferation | 8 | 2020 | 2375 | 0.340 |
Why?
| Smad4 Protein | 2 | 2020 | 38 | 0.320 |
Why?
| Apoptosis | 4 | 2020 | 2499 | 0.310 |
Why?
| Up-Regulation | 3 | 2024 | 839 | 0.300 |
Why?
| Fats | 1 | 2008 | 14 | 0.290 |
Why?
| Mutation | 3 | 2015 | 3710 | 0.290 |
Why?
| Mice, Transgenic | 10 | 2020 | 2117 | 0.290 |
Why?
| Drug Resistance, Neoplasm | 7 | 2017 | 756 | 0.280 |
Why?
| Neoplastic Stem Cells | 2 | 2022 | 379 | 0.270 |
Why?
| Reactive Oxygen Species | 1 | 2009 | 596 | 0.270 |
Why?
| Glucose | 2 | 2011 | 1001 | 0.260 |
Why?
| Xenograft Model Antitumor Assays | 6 | 2020 | 812 | 0.260 |
Why?
| rac1 GTP-Binding Protein | 2 | 2017 | 54 | 0.260 |
Why?
| Keratinocytes | 3 | 2023 | 242 | 0.260 |
Why?
| Wound Healing | 2 | 2018 | 306 | 0.250 |
Why?
| Genes, p53 | 2 | 2020 | 70 | 0.240 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1556 | 0.240 |
Why?
| Disease Models, Animal | 7 | 2023 | 4057 | 0.240 |
Why?
| Carcinogenesis | 2 | 2023 | 213 | 0.220 |
Why?
| Dermatitis | 1 | 2023 | 19 | 0.210 |
Why?
| Phosphatidylinositols | 1 | 2023 | 57 | 0.210 |
Why?
| Receptors, Interleukin | 1 | 2023 | 43 | 0.210 |
Why?
| Carcinogens | 1 | 2023 | 110 | 0.200 |
Why?
| Humans | 35 | 2024 | 129271 | 0.200 |
Why?
| Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.200 |
Why?
| Antineoplastic Agents | 4 | 2017 | 2054 | 0.200 |
Why?
| Glycerol | 1 | 2002 | 91 | 0.200 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 3 | 2017 | 62 | 0.200 |
Why?
| Phosphorylation | 6 | 2015 | 1710 | 0.200 |
Why?
| Immunologic Memory | 1 | 2024 | 349 | 0.200 |
Why?
| Psoriasis | 1 | 2023 | 87 | 0.200 |
Why?
| Laminin | 1 | 2022 | 69 | 0.190 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2022 | 65 | 0.190 |
Why?
| Neoplasms, Experimental | 2 | 2020 | 170 | 0.180 |
Why?
| Female | 25 | 2021 | 68556 | 0.180 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1344 | 0.180 |
Why?
| Cancer-Associated Fibroblasts | 1 | 2020 | 13 | 0.180 |
Why?
| Keratin-15 | 1 | 2020 | 14 | 0.180 |
Why?
| Radiation Injuries | 1 | 2021 | 135 | 0.170 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 52 | 0.170 |
Why?
| Hyaluronan Receptors | 1 | 2020 | 96 | 0.170 |
Why?
| Tumor Burden | 3 | 2018 | 286 | 0.160 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 90 | 0.150 |
Why?
| Cell Movement | 3 | 2018 | 944 | 0.150 |
Why?
| Receptor, EphB3 | 1 | 2018 | 4 | 0.150 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2024 | 857 | 0.150 |
Why?
| Estradiol | 2 | 2013 | 494 | 0.150 |
Why?
| Protein Binding | 2 | 2015 | 2120 | 0.140 |
Why?
| Estrogen Receptor Modulators | 2 | 2017 | 17 | 0.140 |
Why?
| Multiprotein Complexes | 2 | 2016 | 155 | 0.140 |
Why?
| Lung Neoplasms | 3 | 2023 | 2342 | 0.140 |
Why?
| Aminopyridines | 1 | 2018 | 97 | 0.140 |
Why?
| Morpholines | 1 | 2018 | 122 | 0.140 |
Why?
| Smokers | 1 | 2018 | 138 | 0.140 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 129 | 0.140 |
Why?
| Immunoblotting | 2 | 2011 | 305 | 0.140 |
Why?
| Disease-Free Survival | 2 | 2015 | 645 | 0.130 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2016 | 396 | 0.130 |
Why?
| Estrogen Receptor alpha | 1 | 2017 | 133 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2014 | 256 | 0.130 |
Why?
| Extracellular Matrix | 2 | 2022 | 502 | 0.130 |
Why?
| Quinazolines | 2 | 2017 | 244 | 0.120 |
Why?
| Hyperplasia | 2 | 2013 | 171 | 0.120 |
Why?
| Down-Regulation | 2 | 2015 | 636 | 0.120 |
Why?
| Amphiregulin | 1 | 2015 | 24 | 0.120 |
Why?
| Protein Kinase C-alpha | 1 | 2015 | 37 | 0.120 |
Why?
| Antibodies, Neutralizing | 1 | 2017 | 265 | 0.120 |
Why?
| Neuropeptides | 1 | 2015 | 71 | 0.120 |
Why?
| Carrier Proteins | 2 | 2016 | 742 | 0.120 |
Why?
| Cell Adhesion | 2 | 2022 | 452 | 0.120 |
Why?
| Bone Morphogenetic Proteins | 1 | 2015 | 130 | 0.120 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1049 | 0.120 |
Why?
| Epidermal Growth Factor | 1 | 2015 | 170 | 0.110 |
Why?
| Receptors, Estrogen | 1 | 2017 | 426 | 0.110 |
Why?
| Morphogenesis | 1 | 2015 | 158 | 0.110 |
Why?
| Quinolines | 1 | 2015 | 156 | 0.110 |
Why?
| Gene Expression | 3 | 2014 | 1466 | 0.110 |
Why?
| Transcriptome | 3 | 2018 | 874 | 0.110 |
Why?
| Genes, erbB-2 | 1 | 2013 | 28 | 0.110 |
Why?
| Immunotherapy | 1 | 2018 | 592 | 0.110 |
Why?
| Autophagy | 1 | 2015 | 266 | 0.100 |
Why?
| Receptors, Calcitriol | 2 | 2010 | 54 | 0.100 |
Why?
| Chromatography, Liquid | 1 | 2015 | 424 | 0.100 |
Why?
| Heterografts | 3 | 2018 | 131 | 0.100 |
Why?
| Cell Transformation, Neoplastic | 2 | 2012 | 327 | 0.100 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2013 | 157 | 0.100 |
Why?
| Mammary Tumor Virus, Mouse | 2 | 2011 | 44 | 0.100 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 3 | 2017 | 28 | 0.100 |
Why?
| Cell Line | 3 | 2015 | 2779 | 0.100 |
Why?
| Neoplasm Proteins | 1 | 2015 | 422 | 0.100 |
Why?
| Pyrazoles | 1 | 2015 | 404 | 0.100 |
Why?
| Immunohistochemistry | 2 | 2018 | 1691 | 0.100 |
Why?
| Tandem Mass Spectrometry | 1 | 2015 | 523 | 0.100 |
Why?
| Inflammation | 2 | 2023 | 2737 | 0.090 |
Why?
| Gene Amplification | 3 | 2017 | 105 | 0.090 |
Why?
| Macrophages | 1 | 2019 | 1484 | 0.090 |
Why?
| Mutation, Missense | 1 | 2013 | 317 | 0.090 |
Why?
| Mice, Inbred BALB C | 3 | 2023 | 1247 | 0.090 |
Why?
| Skin Neoplasms | 1 | 2018 | 824 | 0.090 |
Why?
| Transcription, Genetic | 1 | 2017 | 1416 | 0.090 |
Why?
| Alkylating Agents | 1 | 2010 | 24 | 0.090 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2013 | 197 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2019 | 1933 | 0.090 |
Why?
| Calcitriol | 1 | 2010 | 55 | 0.090 |
Why?
| Tumor Cells, Cultured | 3 | 2020 | 942 | 0.080 |
Why?
| Ovarian Neoplasms | 1 | 2015 | 489 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2018 | 1290 | 0.080 |
Why?
| BRCA1 Protein | 1 | 2010 | 65 | 0.080 |
Why?
| Prognosis | 4 | 2020 | 3773 | 0.080 |
Why?
| Phthalazines | 2 | 2020 | 41 | 0.080 |
Why?
| Cetuximab | 2 | 2020 | 94 | 0.080 |
Why?
| Proteomics | 1 | 2015 | 1054 | 0.070 |
Why?
| Polymerase Chain Reaction | 1 | 2011 | 1036 | 0.070 |
Why?
| Cell Death | 1 | 2009 | 354 | 0.070 |
Why?
| L-Lactate Dehydrogenase | 1 | 2008 | 119 | 0.070 |
Why?
| Insulin-Like Growth Factor I | 1 | 2010 | 307 | 0.070 |
Why?
| Calcifediol | 1 | 2007 | 31 | 0.070 |
Why?
| Vitamin D | 1 | 2010 | 385 | 0.070 |
Why?
| Models, Biological | 2 | 2018 | 1722 | 0.070 |
Why?
| Oxidative Phosphorylation | 1 | 2008 | 187 | 0.070 |
Why?
| Gene Expression Profiling | 1 | 2013 | 1688 | 0.070 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2011 | 311 | 0.070 |
Why?
| Piperazines | 2 | 2020 | 341 | 0.070 |
Why?
| Antibodies, Monoclonal | 1 | 2013 | 1367 | 0.070 |
Why?
| Enzyme Activation | 1 | 2008 | 812 | 0.070 |
Why?
| Carcinoma | 1 | 2008 | 215 | 0.070 |
Why?
| Kidney Neoplasms | 1 | 2010 | 348 | 0.070 |
Why?
| Skin | 2 | 2023 | 726 | 0.060 |
Why?
| MAP Kinase Signaling System | 2 | 2011 | 313 | 0.060 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2008 | 538 | 0.060 |
Why?
| Cell Survival | 3 | 2015 | 1075 | 0.060 |
Why?
| Molecular Targeted Therapy | 2 | 2020 | 390 | 0.060 |
Why?
| Glycolysis | 1 | 2008 | 311 | 0.060 |
Why?
| Phenotype | 3 | 2023 | 3074 | 0.060 |
Why?
| Blotting, Western | 3 | 2016 | 1204 | 0.060 |
Why?
| Neoplasm Metastasis | 2 | 2018 | 610 | 0.060 |
Why?
| Kaplan-Meier Estimate | 2 | 2018 | 851 | 0.060 |
Why?
| Lipid Metabolism | 1 | 2008 | 497 | 0.060 |
Why?
| Mice, Inbred C57BL | 3 | 2021 | 5439 | 0.060 |
Why?
| Fluorescent Antibody Technique | 2 | 2018 | 376 | 0.050 |
Why?
| MCF-7 Cells | 2 | 2014 | 116 | 0.050 |
Why?
| Histocompatibility Antigens Class I | 1 | 2024 | 200 | 0.050 |
Why?
| Nuclear Proteins | 1 | 2008 | 659 | 0.050 |
Why?
| Phosphothreonine | 1 | 2002 | 6 | 0.050 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2023 | 171 | 0.050 |
Why?
| Protein Phosphatase 2C | 1 | 2002 | 15 | 0.050 |
Why?
| Osmosis | 1 | 2002 | 17 | 0.050 |
Why?
| Glutathione Transferase | 1 | 2002 | 102 | 0.050 |
Why?
| Protein Transport | 2 | 2017 | 428 | 0.050 |
Why?
| Cell Cycle Proteins | 2 | 2020 | 584 | 0.050 |
Why?
| Myeloid Cells | 1 | 2023 | 141 | 0.050 |
Why?
| Biomarkers, Tumor | 2 | 2019 | 1173 | 0.050 |
Why?
| Gene Products, tat | 1 | 2021 | 21 | 0.050 |
Why?
| Catalytic Domain | 1 | 2002 | 218 | 0.050 |
Why?
| Luminescent Proteins | 1 | 2002 | 174 | 0.050 |
Why?
| Plasmids | 1 | 2002 | 358 | 0.050 |
Why?
| Mitochondria | 1 | 2008 | 877 | 0.050 |
Why?
| Green Fluorescent Proteins | 1 | 2002 | 385 | 0.040 |
Why?
| Microscopy, Fluorescence | 1 | 2002 | 398 | 0.040 |
Why?
| Disease Progression | 2 | 2020 | 2630 | 0.040 |
Why?
| Epithelium | 2 | 2012 | 311 | 0.040 |
Why?
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 24 | 0.040 |
Why?
| Dogs | 1 | 2021 | 382 | 0.040 |
Why?
| Feedback, Physiological | 1 | 2020 | 76 | 0.040 |
Why?
| Protein Structure, Tertiary | 1 | 2002 | 841 | 0.040 |
Why?
| SOXB1 Transcription Factors | 1 | 2020 | 57 | 0.040 |
Why?
| Recombinant Fusion Proteins | 1 | 2002 | 648 | 0.040 |
Why?
| Transcription Factors | 1 | 2008 | 1647 | 0.040 |
Why?
| Prostatic Neoplasms | 1 | 2007 | 1016 | 0.040 |
Why?
| Temperature | 1 | 2002 | 634 | 0.040 |
Why?
| Epithelial Cells | 2 | 2019 | 1063 | 0.040 |
Why?
| Clodronic Acid | 1 | 2019 | 12 | 0.040 |
Why?
| Kinetics | 1 | 2002 | 1644 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 2019 | 86 | 0.040 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 383 | 0.040 |
Why?
| Pregnancy | 1 | 2011 | 6391 | 0.040 |
Why?
| Radiation Injuries, Experimental | 1 | 2018 | 23 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 588 | 0.040 |
Why?
| RNA, Neoplasm | 1 | 2018 | 87 | 0.040 |
Why?
| Guinea Pigs | 1 | 2018 | 157 | 0.040 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 207 | 0.040 |
Why?
| Saccharomyces cerevisiae | 1 | 2002 | 530 | 0.040 |
Why?
| Radiotherapy, Image-Guided | 1 | 2018 | 34 | 0.040 |
Why?
| Hyaluronic Acid | 1 | 2020 | 214 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2002 | 2011 | 0.040 |
Why?
| Fibrosis | 1 | 2020 | 520 | 0.040 |
Why?
| Nitric Oxide | 1 | 2023 | 901 | 0.040 |
Why?
| Maytansine | 1 | 2017 | 16 | 0.040 |
Why?
| rho Guanine Nucleotide Dissociation Inhibitor beta | 1 | 2017 | 4 | 0.040 |
Why?
| DNA Repair | 1 | 2019 | 206 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 399 | 0.040 |
Why?
| Cyclin D1 | 1 | 2017 | 63 | 0.030 |
Why?
| Monocytes | 1 | 2020 | 551 | 0.030 |
Why?
| Trastuzumab | 1 | 2017 | 101 | 0.030 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 44 | 0.030 |
Why?
| Cell Cycle | 2 | 2010 | 589 | 0.030 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 39 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2018 | 385 | 0.030 |
Why?
| Time Factors | 2 | 2010 | 6543 | 0.030 |
Why?
| RNA Interference | 1 | 2018 | 450 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2016 | 57 | 0.030 |
Why?
| Fibroblast Growth Factors | 1 | 2017 | 169 | 0.030 |
Why?
| DNA Damage | 1 | 2018 | 383 | 0.030 |
Why?
| Bone Morphogenetic Protein Receptors | 1 | 2015 | 6 | 0.030 |
Why?
| Ligands | 1 | 2017 | 621 | 0.030 |
Why?
| In Vitro Techniques | 1 | 2017 | 1085 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2018 | 1199 | 0.030 |
Why?
| Organ Culture Techniques | 1 | 2015 | 153 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 119 | 0.030 |
Why?
| Spheroids, Cellular | 1 | 2015 | 77 | 0.030 |
Why?
| c-Mer Tyrosine Kinase | 1 | 2014 | 44 | 0.030 |
Why?
| Biomarkers | 2 | 2018 | 3968 | 0.030 |
Why?
| Coculture Techniques | 1 | 2014 | 223 | 0.030 |
Why?
| Genes, myc | 1 | 2013 | 49 | 0.030 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 40 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2015 | 483 | 0.030 |
Why?
| Ki-67 Antigen | 1 | 2013 | 108 | 0.030 |
Why?
| Cisplatin | 1 | 2015 | 299 | 0.030 |
Why?
| Neoplasm, Residual | 1 | 2013 | 120 | 0.030 |
Why?
| Gene Dosage | 1 | 2013 | 143 | 0.030 |
Why?
| DNA Copy Number Variations | 1 | 2013 | 168 | 0.030 |
Why?
| Phagocytosis | 1 | 2014 | 362 | 0.030 |
Why?
| Drug Synergism | 1 | 2013 | 370 | 0.020 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 231 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 758 | 0.020 |
Why?
| Cluster Analysis | 1 | 2013 | 479 | 0.020 |
Why?
| Treatment Outcome | 2 | 2018 | 10202 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2011 | 140 | 0.020 |
Why?
| Postpartum Period | 1 | 2014 | 332 | 0.020 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2013 | 201 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 756 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2011 | 52 | 0.020 |
Why?
| Neoadjuvant Therapy | 1 | 2013 | 381 | 0.020 |
Why?
| Alkylation | 1 | 2010 | 24 | 0.020 |
Why?
| Cyclin A | 1 | 2010 | 17 | 0.020 |
Why?
| Proto-Oncogene Proteins | 1 | 2014 | 635 | 0.020 |
Why?
| Oligonucleotides, Antisense | 1 | 2011 | 113 | 0.020 |
Why?
| Quality of Life | 1 | 2022 | 2687 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2010 | 214 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1269 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2010 | 65 | 0.020 |
Why?
| Caspases | 1 | 2010 | 245 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2010 | 157 | 0.020 |
Why?
| Male | 4 | 2020 | 63517 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2010 | 148 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 184 | 0.020 |
Why?
| Interleukin-6 | 1 | 2011 | 720 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 947 | 0.020 |
Why?
| Estrogens | 1 | 2010 | 346 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2010 | 1304 | 0.020 |
Why?
| Cytokines | 1 | 2014 | 2013 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2010 | 713 | 0.020 |
Why?
| Biological Transport | 1 | 2007 | 404 | 0.020 |
Why?
| Adenocarcinoma | 1 | 2012 | 898 | 0.010 |
Why?
| Cells, Cultured | 1 | 2010 | 4077 | 0.010 |
Why?
| Aged | 1 | 2018 | 22032 | 0.010 |
Why?
| Middle Aged | 1 | 2018 | 31091 | 0.010 |
Why?
|
|
Young's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|